The FDA may soon join forces with personal genomics companies like 23andMe and CIMR in order to draw associations between genotypes and adverse drug reactions. ScienceBlogger Revere from Genetic Future posted that before such a collaborationis considered, genomics companies must recruit more—and more diverse—participants and improve methodology to gather "extremely accurate and detailed" clinical data about them and their drug regimens. "Any genome-wide association study is only as good as the clinical data it's based around," he wrote.
- Log in to post comments
More like this
Pharmacogenomics Reporter (subscription required) describes an intriguing twist in the ongoing struggle between the nascent personal genomics industry and regulatory bodies: apparently the FDA is exploring the possibility of collaborating with consumer genomics providers to track adverse drug…
Yesterday I discussed the decision of personal genomics company 23andMe to slash its price for a genome scan by 60%, to under $400.
In the comments to that post, industry observer David Hamilton pointed me to an article he's written for BNET on the implications of 23andMe's price plunge, which (…
It's been an intensive week of genomics here at the American Society of Human Genetics meeting, and I haven't been able to grab time to blog as much as I'd have liked. In fact there's a whole load of genomics news I'll be trying to cover in some detail over the next couple of weeks; for the moment…
Personal genomics company 23andMe has always differentiated itself from its more sober competitors through an emphasis on collaborative, consumer-driven research - essentially, encouraging its customers to contribute their genetic and trait data to internal research projects designed to find new…